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ABSTRACT 
Cycloartane-triterpenes (cycloartenol, 3α-cycloartenol-26-oic acid and 3β-cycloartenol-26-oic acid) together with α-amyrin acetate 
and flavonoids (pinostrobin, tectochrysin and chrysin) were isolated from Egyptian propolis for the first time. Their antioxidant 
activity was evaluated with DPPH and superoxide anion radical (O2
.-). All compounds possessed both (O2
.-) scavenging as well as XOD 
inhibitory activity in the range of 50 – 75 %. With DPPH, only the flavonoids showed scavenging activity (48 – 83 %). 
Acetylcholinesterase (AChE) and phosphodiesterase type 4 (PDE4) inhibitors are currently considered as intracellular targets for 
treatment of Alzheimer’s disease and Chronic obstructive pulmonary disease (COPD). 3β-cycloartenol-26-oic acid moderately 
inhibited AChE and PDE4 activities in vitro with IC50 values of 0.8±0.2 and 1.9±0.4 µM, respectively, while 3-cycloartenol-26-oic acid 
inhibited AChE activity with an IC50 value of 2.1±0.1 µM. The flavonoids pinostrobin and chrysin reduced PDE4 activity by 43 and 40 
%, respectively (10 µM) as well as moderately inhibited the growth of the HepG2 cell line, whereas chrysin reduced proliferation of 
NIH-3T3 cells at 50 µM. Therefore, our results with 3β- and 3-cycloartenol-26-oic acids can contribute to further research on 
alternative drugs for the treatment of neurological and neurodegenerative diseases, as well as asthma and COPD.  
Keywords: Propolis, Acetylcholinesterase (AChE), Phosphodiesterase (PDE4), Cycloartane triterpenes, Radical scavenging activity. 
 
INTRODUCTION 
lzheimer’s disease (AD) is characterized as a 
progressive neurodegenerative disorder and 
considered as prominent cause of dementia in the 
elderly. The treatment of AD is a clinical challenge. AD is 
estimated to account for 50-60% of dementia cases in 
persons over 65 years of age.1 One important change 
observed in the brain of AD patients is a decrease in level 
of the neurotransmitter acetylcholine (ACh) by nearly 
90%, which affects behavioral aspects and causes 
impairment in cognitive function.2 Acetylcholinesterase 
hydrolyzes the neurotransmitter acetylcholine and is a 
major therapeutic target for the symptomatic treatment 
of Alzheimer's disease. Oxidative balance is emerging as 
an important issue in understanding the pathogenesis of 
Alzheimer's disease.3 Examination of Alzheimer's disease 
brain has demonstrated a great deal of oxidative damage, 
associated with both hallmark pathologies (senile plaques 
and neurofibrillary tangles) as well as in normal appearing 
pyramidal neurons.  
COPD is a major cause of morbidity and mortality and is 
currently the fourth most common cause of death in the 
world according to the World Health Organization (WHO). 
The WHO estimates that by 2020, COPD will be the third 
leading cause of death and the fifth leading cause of 
disability worldwide.4 
The selective targeting of phosphodiesterases type 4 
(PDE4) has been actively pursued as a novel therapeutic 
approach in the treatment of respiratory diseases 
associated with inflammatory processes, such as asthma 
and COPD. PDE4 represents the major class of PDEs 
expressed in human inflammatory cells and in particular 
in macrophages and neutrophils, the main cell types 
present in the lungs of COPD patients.5 The ability of 
compounds to inhibit PDE4 enzymatic activity is 
correlated with their anti-inflammatory potency.6 PDE4 
catalyzes the cleavage of the second messenger cyclic 
adenosine monophosphate, (cAMP) to AMP, and plays a 
role in anti-inflammatory responses.7 
Oxidative stress is an important feature in the 
pathogenesis of COPD. Targeting oxidative stress with 
antioxidants or boosting the endogenous levels of 
antioxidants is likely to be beneficial in the treatment of 
COPD.8 
Bioflavonoids possess both antioxidant and anti-
inflammatory properties and hence may influence chronic 
inflammatory diseases such as COPD.9 Triterpenoids 
exhibited several types of pharmacological activities 
including improvements of some central nervous system 
disorders.10 
Propolis is a resinous hive product collected by the bees, 
rich in bioflavonoids and terpenoid compounds.11,12 
Propolis has antioxidant12, anti-inflammatory13, 
antibacterial, antifungal11, antiviral12 and antitumor 
activities.14 
The aim of the present study was to reveal further 
interesting bioactivities including the search for potential 
xanthine oxidase; acetylcholinesterase and 
phosphodiesterase type 4 inhibitors from Egyptian 
propolis.   
Bioactive Metabolites from Propolis Inhibit Superoxide Anion 
Radical, Acetylcholinesterase and Phosphodiesterase (PDE4)
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MATERIALS AND METHODS 
General 
NMR spectra were measured on a Bruker DRX 500 
spectrometer (Bruker Biospin, Rheinstetten, Germany). 
1H- and 13C-NMR and HMBC spectra were measured using 
an inverse-detection probe (5 mm). Operating 
frequencies were 500.13 MHz for acquiring 1H-NMR and 
125.75 MHz for 13C-NMR spectra. Samples were 
measured at 300 K in CD3OD with TMS as an internal 
standard. Electrospray ionization mass spectra (ESIMS) 
(positive mode) were measured with a Hewlett Packard 
(Avondale, PA, USA). Silica gel (0.063 – 0.200 mm) and 
Sephadex LH-20 were used for column chromatography 
(CC). Silica gel F-254 was used for analytical thin layer 
chromatography.  
Propolis 
Egyptian propolis was collected from Gharbia province of 
east area of Nile Delta, Egypt. The sample was collected 
during March 2010.  
Extraction and isolation 
Propolis (1 kg) was cut into small pieces and extracted 
with distilled water (2 L x 3) each for 2 hours at 85 C 
(PWE), the residue was extracted with 70% ethanol (2 L x 
3) under reflux for 2 h (PEF 70%). The residue was again 
extracted with absolute ethanol (2 L x 3) under reflux 
condition for 2 h to give propolis ethanol fraction (PEF, 50 
g) after evaporation. The PEF gave a higher yield than the 
two other extracts (10 g PWE and 8 g PEF 70%).The PEF 
(50 g) was subjected to Sephadex LH-20 column 
chromatography (100 x10 cm). Stepwise gradient elution 
was carried out using a solvent system of decreasing 
polarity starting with 100% water, water–methanol and 
then methanol-methylene chloride. Fractions of 500 ml 
were collected and investigated by TLC (silica gel DF 245). 
Chromatograms were visualized under UV light before 
and after exposure to 50% sulfuric acid in methanol. 
Similar fractions were combined and concentrated to 
dryness under reduced pressure to obtain four main 
fractions. These fractions were further purified on silica 
gel columns. Two terpenoid fractions were obtained, the 
1st was eluted with n-hexane to give the triterpenoid 4 
(α–amyrin acetate, 10 mg) and the 2nd eluted with 
toluene: ethyl acetate (9: 0.5) to give the triterpenoids 1 
(3β-cycloartenol, 24 mg), 2 (3α-cycloartenol-26-oic acid, 
20 mg) and 3 (3β-cycloartenol-26-oic acid, 18 mg). Two 
flavonoid fractions were eluted with petroleum ether: 
ethyl acetate (8:2) and petroleum ether: ethyl acetate 
(6:4) to give three flavonoids: 5 (pinostrobin, 12 mg), 6 
(tectochrysin, 5 mg) and 7 (chrysin, 9 mg).  
3β-Cycloartenol (1): 1H-NMR (500 MHz, CDCl3)showed a 
cyclopropyl methylene (δ 0.31 and 0.55 d, J = 4.1 Hz) of 
cycloartane-triterpene, methyl groups at δH 0.81-(s,3H-
30), δH-0.86-(s, 3H-21)  δH-0.88 (s, 3H-28), δH 0.96-( d, J = 
6.3 Hz, 3H-29), and one olefinic proton at δH 5.12 (t, J = 
7.0 Hz), signal of  hydroxymethine proton at δH 3.3 (dd, J 
= 11.0, 3.0 Hz). 13C-NMR (125 MHz, CDCl3) seven  methyl 
groups at δ 14.01 (C-30) δ 17.64 (C-27), δ 18.04 (C-18), δ 
18.21 (C-21), δ 19.31 (C-28), δ 25.44 (C-29), δ 25.72 (C-
26), and double bond appeared at δ125.0 (C-24), δ130.9 
(C-25) with hydroxymethine at  δ 78.25 (C-3) and the 
characteristic signals for cyclopropane at δc 29.3(C–19). 
EIMS showed a molecular ion at m/z 426 suggested a 
molecular formula of C30H50O.                                                            
3-Cycloartenol-26-oic acid (2): The MS spectrometry of 
compound 2 showed a molecular ion peak at m/z 456 
with 30 mass unit differences from compound 1. The 
comparison of 1H-NMR and 13C-NMR spectra of 
compound 2 with compound 1 showed a close similarity 
except for downfield shift for the olefinic double bond by 
δ∆ 1.53 and δ∆ 17.10 in the proton and carbon 
respectively suggested withdrawing neighbor group. From 
the mass difference with compound 1 and the additional 
signal in 13C-NMR at δ 168.8 for compound 2 assuming 
the presence of carboxylic group. The position of the 
carboxyl group was determined by HMBC correlation of 
the 3H-27(δ 1.74) with C-25, C-24 and C-27which 
indicates to the carboxylic group at C-26 position. The 
above finding confirmed the proposed structure is 3-
Cycloartenol-26-oic acid.15,16 
3-Cycloartenol-26-oic acid (3): The EI/ MS of compound 
3, exhibited the molecular ion peak at m/z 456 suggesting 
the similarity of compound 2. The Comparison of 1H-NMR 
and 13C-NMR spectra of compound 3 with 2 showed a 
complete agreement except for the configuration of 
hydroxyl group at C-3 position. This was deduced from 
upfield shift in 1H-NMR H-3 by δ∆ 0.13 while downfield 
shift of C-30 at 13 C- NMR by δ∆ 6.30. The above Data 
confirmed the proposed structure as 3-Cycloartenol-26-
oic acid.15,16 
Alpha-amyrin acetate (4): 1H-NMR (500 MHz, CDCl3) δ 
0.73-(s, 3H-28), δ 0.77(s, 3H-24), δ 0.82-(s, 3H-29), δ 0.91-
(s, 3H-30), δ 0.97-(s, 3H-23), δ 1.05-(s, 3H-26), δ 1.06-(s, 
3H-25), δ 1.20-(s, 3H-27), δ 1.99-(s, Ac), one olefinic 
proton observed at δ 5.05 (1H, t, J = 4.0 Hz, H-12), and 
oxymethine at  δ 4.51(1H, dd, J = 5.1; 11.2 Hz, H-3).13C 
NMR (125 MHz, CDCl3) confirmed the presence of nine  
methyl group at δ 16.75-(C-25), δ 16.88-(C-24) δ 17.51-(C-
26), δ 18.26(C-29), δ 21.32(C-30) δ 23.24-(C-27), δ 28.08-
(C-28), δ 28.08-(C-23),  and the double bond at δ 124.33 
(C-12), δ 139.64 (C-13) with oxymethine at δ 80.90 (C–3), 
and presence of a signal  at δ171.00 suggest an acetyl 
group.                       
Pinostrobin (5): Electrospray ionization mass 
spectrometry (ESI-MS) m/z 271 [M+H]+, 1H-NMR (DMSO-
d6) exhibited a flavonoid pattern and showed signals at  δ 
12.1(1H, s, 5-OH),7.53 (2H,br.d, J = 7.5,   ,H-2`,H-6`), δ 
7.56 (3H, m, H-3`,H-4`, H-5`) ,δ 6.12 (1H ,d , J = 2.7 Hz, H-
6), δ 6.16 (1H,d, J = 2.7 Hz, H-8), δ5.63 (1H, dd, J 
=12.8,2.7, Hz, H-2), δ3.8 (3H, s,7-OMe), δ 3.06 (1H, dd, J 
=15.1,12.8 Hz, H-3a), δ2.85 (1H, dd, J=14.6, 2.7 Hz, H-
3b).13C-NMR : δ196.5 (C-4), δ 167.4 (C-7), δ163.18 (C-9), 
δ162.63 (C-5), δ 138.5 (C-1`), δ 128.5 (C-4`), δ 128.6 (C-
5`,C-3`), δ 126.63 (C-6`,C-2`), δ 102.6 (C-10), δ 94.75 (C-8), 
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δ 93.87(C-6), δ 78.54(C-2), δ 55.92 (C-7-OMe), δ 42.11(C-
3). 
Tectochrysin (6): ESI-MS m/z 269 [M+H]+.1H-NMR (DMSO-
d6): δ 12.8 (1H ,s,5-OH) ,  δ8.1(2H ,d, J=7, H-2`,H-6`), δ 
7.59 (3H, m, H-3`,H-4`,H-5`) , δ7.07(1H, s, H-3),  signal at δ 
6.84 (1H,d , J = 2 Hz, H-8),  δ 6.4 (1H ,d , J =2.5 Hz, H-6), 
δ3.9(3H , s,7-OMe) ; 13C-NMR : δ182.1 (C-4), δ165.36 (C-
2), δ163.46 (C-7), δ161.17 (C-5), δ157.38 (C-9), δ 132.16 
(C-4`), δ 130.58 (C-1`), δ 129.15 (C-3`, C-5`), δ 126.46 (C-
2`, C-6`), δ 105.35 (C-3), δ 104.93 (C-10),  δ 98.17 (C-6), δ 
92.83 (C-8), δ 56.11 (C-7-OMe).  
Chrysin (7): ESI-MS m/z 255[M+H]+.1H-NMR (DMSO-d6): δ 
12.84 (s, OH-5), δ 8.09 (d, J = 7 Hz, H-2; H-6), δ 7.59 (m, 
H-3, H-4, H-5), δ 7.04 (s, H-3), δ 6.86 (d, J = 1.5, H-8), δ 
6.46 (d, J = 1.5, H-6). 13C-NMR: δ 181.9 (C-4), 164.5 (C-2), 
163.1 (C-7), 161.4 (C-5), 157.4 (C-9), 132.0 (C-4), 130.7 (C-
1), 129.1 (C-3, C-5), 126.4 (C-2, C-6), 105.2 (C-3), 104.0 
(C-10), 99.0 (C-6), 94.1 (C-8).  
DPPH radical scavenging activity 
DPPH radical scavenging activity of compounds (1-7) was 
analyzed according to a modified procedure of 
Matsushigeet al.171 ml of methanol solution for each 
compound (50µg/ml) was added to 1 ml of methanol 
solution of DPPH (60µM). The prepared solutions were 
mixed and left for 30 min at room temperature. The 
optical density was measured at 520 nm using a 
spectrophotometer (UV-1650PC Shimadzu, Japan). Mean 
of three measurements for each compound was 
calculated.  
Superoxide anion scavenging activity. 
Superoxide anion scavenging activity was determined 
according to a modified method of Matsushigeet 
al.17Reaction mixtures containing 1.4 mL of 50 mM 
Na2CO3 (pH 10.2), 100 µL of 3 mM xanthine, 100 µL of 3 
mM EDTA, 100 µL of BSA (1.5 mg/mL), 100 µL of 75 mM  
Nitro blue tetrazonium, and 50 µL of each compound 
(50µg/ml)  were preincubated at 30 °C for 10 min, and 50 
µL of xanthine oxidase (0.3 unit/mL) was added. After 
incubation at 30 °C for 20 min, 200 µL of 6 mM CuCl2 was 
added to stop the reactions and the absorbance was 
measured at 560 nm.  
Acetylcholinesterase (AChE) inhibition assay 
AChE activity was measured by adapting the colorimetric 
assay described by Ellmanet al.18 for a microplate test 
system. As positive control the reversible and specific 
inhibitor huperzine at a concentration of 0.1 µM was 
used. The determined IC50 value of huperzinewas0.12 µM. 
Phosphodiesterase (PDE4) inhibition assay 
The activity of phosphodiesterase PDE4 was measured 
using the PDE Light HTS cAMPphosphodiesterase kit 
(catalogue number LT07-600, Lonza, Rockland, USA) 
according to the manufacturer's instructions. For the 
inhibition of PDE4 1µM and 10 µM of the competitive and 
reversible inhibitor rolipram were applied as positive 
control. The determined IC50 value of rolipram was 0.75 
µM. The calculation of the IC50 values of the enzyme 
inhibitory activities was performed by using the software 
Graph Pad Prism 5 (Graph Pad software, La Jolla, USA). 
Cytotoxic assays (the CellTiter-BlueCell Viability Assay) 
The sensitivity of the cell lines HepG2 and NIH-3T3 
(Mouse embryonic fibroblast cell line) to the isolated 
compounds was evaluated by monitoring the metabolic 
activity using the CellTiter-BlueCell Viability Assay 
(Promega, Mannheim, Germany). The human 
hepatocellular carcinoma cell line HepG2 was obtained 
from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). The mouse 
fibroblast cell line was kindly provided by G. Rimbach 
(University of Kiel, Germany). HepG2 and NIH-3T3 cells 
were maintained in RPMI 1640 medium. Media were 
supplemented with 10% foetal bovine serum (Promocell, 
Heidelberg, Germany), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen, Carlsbad, CA, USA). The cultures 
were maintained at 37°C under a humidified atmosphere 
and 5% CO2. The cell lines were transferred twice every 3 
or 4 days and the culture medium changed 48 hours after 
transfer. For experimental procedures, cells were seeded 
in 96-well plates at concentrations of 10,000 cells 
(HepG2) and 7,500 cells (NIH-3T3) per well. After 24 h 
incubation the medium was removed and 100 µl of the 
test sample adjusted to final concentrations of 10 and 50 
µM by diluting in growth medium were added to the cells. 
Each sample was prepared in triplicate. 25 µM Tamoxifen, 
as a standard therapeutic drug, was applied as positive 
control. Following compound addition, plates were 
cultured for 24 h at 37°C. Afterwards, the assay was 
performed according to the manufacturer's instructions. 
Cells were incubated for 2 h at 37°C. Fluorescence was 
measured using the microplate reader Infinite® M200 
(Tecan, Männedorf, Switzerland) at excitation 560 nm and 
emission 590 nm. 
RESULTS 
Structure determination of the isolated compounds 
Based on 1D, 2D-NMR spectral data and mass 
spectrometry compound 1 was identified as 3β-
cycloartenol.19The structures of compounds 2 and 3 were 
established by comparison of their spectroscopic data 
with compound1. The MS of 2 and 3 exhibited to m/z at 
456 with 30 mass unit difference from compound 1. The 
analysis of 1H and 13C spectroscopic data confirmed the 
structure of compounds2 and 3 as 3-cycloartenol-26-oic 
acid and 3-cycloartenol-26-oic acid respectively and 
their data are in accordance with the reported 
literature.15,16 The MS and 13C-data of compound 4 are in 
agreement with α-amyrin acetate structure.19 The 
flavonoid compounds 5, 6 and 7 were identified by UV, 
MS and NMR spectroscopic data as pinostrobin, 
tectochrysin and chrysin respectively20, (Fig. 1). 
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The DPPH free radical scavenging activity 
Tectochrysin and chrysin showed inhibition of 83 % and 
74 % respectively, while pinostrobin showed moderate 
inhibition of 48 % (Fig. 2).  The triterpenoid compounds 
(1-4) showed no activity.   
Scavenging ability for superoxide anion radical  
The free radical scavenging activity on superoxide anion 
radical generated by an enzymatic method (X-XOD 
system) was evaluated. Compounds 2 and 3 were the 
most active compounds (68 and 75 % scavenging activity 
at a concentration of 50 µg/ml, while the other isolated 
compounds revealed moderate antioxidant activity of 50 - 
59 % (Fig. 2). 
Acetylcholinesterase (AChE) inhibition 
Inhibitory activity of the compounds isolated from 
Egyptian propolis on the recombinant enzyme AChE was 
analyzed. All flavonoid compounds as well as α-amyrin 
acetate (compounds 4-7) showed no inhibitory activity of 
AChE, while the cycloartane-triterpenoid compounds 
(compounds 1-3) inhibited acetylcholinesterase (AChE) in 
the range of 60 – 92 %, at a concentration of 10 µM (Fig. 
3). Compound 3exhibited the highest activity with an IC50 
= 0.8 ±0.2µM. 
Phosphodiesterase (PDE4) inhibition  
The isolated compounds were evaluated toward the 
enzyme PDE4. Compounds 1, 4 and 6 showed no 
inhibitory activity of PDE4, while compounds 3, 5 and 7 
showed significant inhibition of PDE4 in the range of 40 – 
75 %, at a concentration of 10 µM (Fig. 3). Compound3 
had the highest activity with an IC50 value of1.9±0.4 µM. 
Evaluation of potential cytotoxicity  
The flavonoids pinostrobin and chrysin showed moderate 
anti-proliferative activity against HepG2 cell line (at 50 
µM). Chrysin showed a significant activity than that of 
pinostrobin (46 %, Fig. 4), while the terpenoid compounds 
showed no activity. Finally, the flavonoid chrysin is the 
only compound showed weak growth inhibitory activity 
against the NIH-3T3 cell line (31%, at 50 µM) (Fig. 4). 
 
 
Figure 1: Chemical structures of the isolated compounds from Egyptian propolis. 
 
 
Figure 2:  Free radical scavenging activity of propolis compounds (1-7) in the DPPH radical and the xanthine- XOD assays. 
Values are expressed as mean ± SD, n = 3 at a concentration of (50 µg/ml for all tested compounds).  
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Figure 3: Inhibition of the acetylcholinesterase and phosphodiesterase activities by propolis compounds (1-7). Values are 
expressed as mean ±SD, n = 3 at a concentration of 10 µM including the positive controls rolipram (10 µM) and huperzine 
(0.1 µM). 
 
 
Figure 4: Cytotoxic activity of propolis isolated compounds (1-7) against HepG2 and NIH-3T3 cell lines). Values are 
expressed as mean ±SD, n = 3 at a concentration of 50 µM. 
 
DISCUSSION 
AChE inhibitors have received considerable attention as 
alternatives in treatment of Alzheimer's disease. PDE4 
inhibitors appear to confer benefit in improving lung 
function. The damage caused by reactive oxygen species 
is considered a contributing factor to several diseases 
including AD3 and COPD.8 Bioflavonoids possess both 
antioxidant and anti-inflammatory properties and hence 
may influence chronic inflammatory diseases such as 
COPD.9 
Work on bioactive compounds from Egyptian propolis has 
led to the isolation and structure elucidation of several 
exciting phytoconstituents having significant AChE and 
PDE4 inhibitory activity, along with mild anti-proliferative 
effect against HepG2 and NIH-3T3 cell lines (Figs. 3, 4). 
In this study, the isolated flavonoids and triterpenoids 
were evaluated for free radical scavenging activity by 
DPPH and xanthin-xanthin oxidase assays. With DPPH, 
only the flavonoids showed highly significant scavenging 
activity (48 – 83 %). All the isolated triterpenoids and 
flavonoids showed significant superoxide anion (O2
•–) 
scavenging activity within the range of 50 – 75 %.   
Superoxide anion is the first generated reactive oxygen 
species (ROS) after oxygen enters living cells. It was once 
considered to be highly deleterious to cell functions and 
aging. Superoxide anion and uncoupling proteins are 
linked to Alzheimer’s disease in mitochondria. 
Simultaneous disorders of superoxide and uncoupling 
proteins create the conditions for neuronal oxidative 
damages. On the one hand, sustained oxidative damage 
causes neuronal apoptosis and eventually, accumulated 
neuronal apoptosis, leading to exacerbations of 
Alzheimer’s disease.21 It was also demonstrated that 
inhibition of superoxide anion production in human 
neutrophils by isopedicinflavanone is associated with an 
elevation of cellular cyclic adenosine 3,5′-monophosphate 
(cAMP) and activation of protein kinase A (PKA) through 
its inhibition of cAMP-specific PDE.22 
In this context, a previous study showed that the 
treatment with the antioxidants vitamins E and C 
significantly decreased the action of AChE activity in 
hippocampus of female adult rats.23 This demonstrates 
the high potential of the cycloartane-triterpenoid 
compounds (1-3), which significantly inhibited the action 
of AChE besides their significant antioxidant activity. In 
another study, moderate inhibitory activity of AChE by 
cycloartenol was found.10Thetriterpenoid3-cycloartenol-
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26-oic acid (2) and 3β-cycloartenol-26-oic acid (3) showed 
the highest significant inhibitionto AChE activity with IC50 
values of 2.1±0.1 and 0.8±0.2µM and antioxidant activity 
68 and 75% at concentration of 50 µg/ml, respectively. 
3β-cycloartenol(1) showed moderate inhibition to AChE 
with an IC50 value of 3.6±0.1 µM as well as antioxidant 
activity of 59% (Figs. 2, 3).  
On the other hand, some of the isolated flavonoids and 
triterpenoids showed PDE4 significant inhibitory 
activities; compound (3) (3-cycloartenol-26-oic acid) and 
the flavonoids (5) and (7) (pinostrobin and chrysin) by (75, 
43 and 40 %, respectively at 10 M). Our results are in 
agreement with some previous studies, which found that 
luteolin flavone non-selectively and competitively 
inhibited PDE424 and biochanin A has the potential for 
treating allergic asthma and COPD.25 Also the flavonoid 
dioclein possesses significant antioxidant and PDE4 
inhibitory activity.26 The triterpenes, betulinic and sericic 
acids, exhibited mild inhibitory activity on the isolated 
PDE4 isozyme.27 Ursolic acid inhibited PDE4 activity with 
an IC50 of 51.21Μ.
28 
PDE4 inhibitors act by increasing intracellular 
concentrations of cAMP, which has a broad range of anti-
inflammatory effects on various key effector cells 
involved in asthma and COPD. Raising cAMP in 
neutrophils inhibits superoxide anion (O2
•–) production.29 
It was suggested that PDE4 inhibitors decreased N-
Formyl-Methionine-Leucine-Phenylalanine (fMLP)-
induced (O2
•–) release in bronchoalveolar lavage (BAL) 
cells enriched in neutrophils but not in macrophages, 
through p44/42(MAPK) activation by a cAMP- and a PKA-
independent mechanism.30 
The above mentioned data support our results, as it is 
clear that all the compounds had superoxide anion (O2
•–) 
scavenging activity (Fig. 2), but some of them showed 
inhibitory activity of PDE4 (Fig. 3), which could mean that 
not all the compounds have the potential to be developed 
into useful new therapeutic agent for treating 
neutrophilic inflammatory diseases. Also, it is clear that 
the pure isolated compounds had mild anti-proliferative 
effect. 
CONCLUSION 
It is the first time to reveal that3β-cycloartenol-26-oic 
acid (3) strongly inhibited acetylcholinesterase and 
phosphodiesterase activities with IC50 values of 0.8±0.2 
and 1.9±0.4 µM respectively, while 3-cycloartenol-26-
oic acid (2) showed the highest inhibition of AChE activity 
with an IC50 value of 2.1±0.1 µM. Both compounds 
exhibited additional antioxidant activity; beside they 
mildly inhibit proliferation of the tested cell lines. These 
results encourage further studies to proof their possible 
application as alternative drugs for the treatment of 
neurological and neurodegenerative diseases, asthma and 
COPD. 
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